WA Collaborative Cancer Research Grant
"CCRG"
GUIDELINES

Contents

1 Introduction 2
2 Purpose / Objective 2
3 Eligibility 3
4 The Tobacco and Other Industries 4
5 Application and Selection Process 4
6 Guidance on completing the Expression of Interest and Full Application 7
7 Scientific Assessment Criteria 8
8 Equipment 9
9 Consumables 9
10 Other Funding Sources 10
11 Publicity and Acknowledgments 10
12 Publications Arising from Grants 10
13 Reporting Obligations 11
14 Program Evaluation 11
15 Insurance 11
16 Requests for Variation 12
17 Research Ethics and Governance 12
18 Use of Data Collections 12
19 Intellectual Property 13
20 Grant Conditions 14
21 Further Information 15

1 Introduction

The WA Collaborative Cancer Research Grant is a joint funding program of the Future Health Research and Innovation (FHRI) Fund and Cancer Research Trust (CRT).

The FHRI Fund provides a secure source of funding to drive health and medical research, innovation, and commercialisation, and through these activities, improve the health and prosperity of all Western Australians. It also provides an opportunity to diversify the economy, create jobs, improve the sustainability of the health system, and position Western Australia (WA) as a leader in research and innovation.

The mission of the CRT is to enable cancer research in WA that is unique, excellent, and collaborative CRT strives to make an internationally significant contribution to the diagnosis, prevention, and treatment of cancer. To achieve this, we are actively driving world-class innovative and collaborative research in WA by securing, funding and supporting exceptional talent.

This collaborative funding scheme promotes the following FHRI Fund Priority Goals as well as the mission and vision of the CRT:

- Provide cash commitments for submission to major competitive co-funding programs, making Western Australian-led applications more competitive and, therefore, increasing the State's share of national and international competitive funding.
- Target high-performing researchers within WA as well as recruiting both nationally and internationally to maintain and/or advance the State's position as a leader in health and medical research.

2 Purpose / Objective

The WA Collaborative Cancer Research Grant (CCRG) has been established to support, energise and fund collaborative and innovative cancer research in WA. It aims to support teams of high caliber researchers to pursue broad based, multi-disciplinary cancer activities, increase the inter-institutional collaboration of WA cancer researchers and increase the teams' competitiveness for State, National and International cancer research funding.

The purpose of the CCRG is to enable a multi-disciplinary group of researchers with established track records to collaborate and generate new and important knowledge for cancer treatment and/or control. Applications that involve the recruitment of senior researchers with outstanding track records (preferably from outside WA), as well as junior researchers (with the clear potential to become research leaders), who are committed to relocating or working for a substantial period in WA, will be viewed favorably.

Applications across the entire breadth of cancer research will be accepted, from fundamental research to clinical/implementation research. This is a unique opportunity, offering the successful team the substantial funding amount of up to $1 million per annum (pa) for 5 to 9 years[1]. This funding is provided via matched funding from the FHRI Fund and the CRT (Funding Partners). The successful recipient is expected to provide additional funding equal to 30% or more of the awarded grant. There will be no indexation on the amount awarded under the CCRG.

CRT will administer the CCRG on behalf of the Funding Partners.

[1] The Grant is for 5 years but is potentially renewable on satisfactory independent review for an additional 4 years (i.e. a total of 9 years' potential funding at $1 million pa).

3 Eligibility

To be eligible for the CCRG, all of the following criteria applies.

3.1 Administering Institution/s

The Administering Institution must:

- have an active Australian Business Number (ABN).
- have a physical and operational presence in WA.
- be a WA university, WA research institution, WA public Health Service Provider[2] or a WA Public-Private Partnership (PPP) provider[3].

Or

- be a NHMRC Approved Administering Institution.

- The grant funding must not constitute the entire financial base of the Administering Institution/s (i.e. the Administering Institution must have other external sources of income).

- Applications must involve two or more Administering Institutions acting in collaboration. One of the Administering Institutions must be nominated as the lead Administering Institution which will receive and administer the CCRG.

- The Administering Institution/s or other entities that fund or are involved in the CCRG must not be part of an industry that produces products or services that may contribute to poor physical health or mental wellbeing of the community.

3.2 Chief Investigator / Co-Chief Investigator (CI/Co-CIs)

The Chief Investigators / Co-Chief Investigators must:

- be an Australian or New Zealand citizen, a permanent resident of Australia, or have an appropriate visa in place for the duration of the grant.
- physically reside in WA for a minimum of 75% of the grant period.
- be based at an eligible Administering Institution in WA for at least 75% of each year for the entire grant period.
- hold a primary research appointment at an eligible Administering Institution in WA for the period of the grant.
- not have current funding from the CRT.
- not have any overdue reports for any grant administered by OMRI (including FHRI Fund programs) from any year (excludes authorised extensions).
- have secured additional funding equating to at least 30% of the CCRG funding and provide relevant documentation when submitting their Full Application.

3.3 Most of the research work (assessed as 75% or more) should be conducted in or through established Western Australian research organisations or hospitals. This does not

[2] WA public health service provider means a health service provider established by an order made under section 32(1)(b) of the Health Services Act 2016, such as the Child and Adolescent Health Service, East Metropolitan Health Service, North Metropolitan Health Service, South Metropolitan Health Service, WA Country Health Service and PathWest.
[3] Public-private partnership (PPP) provider refers to private hospitals with an agreement with the state government to provide public health services, for example, Joondalup Health Campus and St John of God Midland Public Hospital.

preclude interstate or international collaboration; however, it does preclude the expenditure of more than 25% of funds outside WA.

3.4 The Department of Health, FHRI Fund and CRT will not underwrite any costs beyond the funding awarded through the research program.

3.5 The additional funding equating to at least 30% of the CCRG funding must not include National Health and Medical Research Council (NHMRC) grants, Department of Health grants, FHRI Fund grants, overheads levied by any Administering Institution (including indirect costs of research or research infrastructure), existing infrastructure or other existing services.

3.6 The CI/Co-CIs will be responsible for the completion and lodgement of the application/s.

3.7 No changes to the CI/Co-CIs are permitted between the Expression of Interest and Full Application stage, if a change is required due to extenuating circumstances, approval from CRT in writing must be sort immediately.

3.8 The CI/Co-CIs will be responsible for coordinating the research program and ensuring its timely execution.

4 The Tobacco and Other Industries

CRT will not provide a grant to any researcher who is an applicant for, or who is in receipt of, funds from:

- Companies or other entities receiving money or revenues from the tobacco industry or having arrangements or dealings with the tobacco industry which they may actually, potentially, or perceivably compromise tobacco control initiatives. This includes:
    - Tobacco manufacturers or wholesalers, and their subsidiaries or other entities within that group of companies.
    - Entities or individuals whose sole or principal business is the retailing of tobacco products.
    - Other entities identified to have links of a commercial, strategic, or public nature with tobacco manufacturers or wholesalers.
- Companies or other entities involved in manufacturing, distribution, promotion or sale of any other product or service known to cause cancer or to increase cancer risk (including, but not limited to, solaria, asbestos, alcohol, environmental carcinogens, sugared beverages, and other energy dense nutrient poor foods).

CRT will terminate its support for a research program if the above provisions relating to support from these industries are breached or it believes that the integrity of the research is threatened by influence from tobacco or other interests.

Researchers in receipt of funds from other organisations in conflict with the prevention of cancer will be examined closely to determine if a Conflict of Interest exists.

5 Application and Selection Process

5.1 Expression of Interest

The Expression of Interest (EOI) requires:

- a summary of the program of research.

- a description of the Administering Institutions.
- details of the CI/Co-CIs.
- details members of the research team.
- confirmation of the stipulated percentage and actual dollar co-contribution from the additional funding is essential.

Information provided in the EOI will be used to assess applicants' eligibility and competitiveness and will remain confidential.

EOIs will be assessed on their competitiveness by the Cancer Research Expert Evaluation Panel (the Panel), which is an independent assessment panel comprising of internationally recognised cancer researchers.

A select number of candidates will be shortlisted and asked to submit a Full Application. Full Applications are to be submitted to CRT within the timeframe provided. EOIs that were not considered competitive will not be invited to submit a Full Application.

The EOI form is available to download on the CRT website (www.cancerresearchtrust.org.au).

The applicant(s) must prepare and submit the EOI according to the instructions.

The EOI application must be complete and contain all information and supporting documents necessary for assessment and must comply with these guidelines.

EOIs must be submitted by the closing date/time, consideration must be given to the time needed to comply with internal deadlines.

Electronic signatures are acceptable if approval to use the electronic signature has been obtained from that person.

CRT require two copies of the EOI, an electronic copy and a hard copy.

The EOI hardcopy can be mailed to PO Box 226, Subiaco WA 6904 or delivered by hand to Suite 8, 110 Hay Street, Subiaco WA 6008.

EOIs are to be emailed to info@cancerresearchtrust.org.au as a single Adobe Acrobat PDF or Microsoft Word file, not exceeding 5 MBs, including supporting documentation.

The EOI (electronic and hard copy) must be received by: **4:00pm (AWST) Friday 14 November 2025.**

Before submitting your EOI, please ensure all sections have been completed as specified, including sign-off from all CI/Co-CIs listed and the Responsible Officer at the Administering Institution/s.

A select number of EOIs will be shortlisted by the Panel and invited to submit a Full Application.

5.2 Full Application

If an EOI meets all the eligibility requirements in these guidelines, has been submitted in accordance with the instructions and has been deemed competitive by the Panel, the candidate will be invited to submit a Full Application.

The CI/Co-CIs listed on the competitive EOI will be emailed and invited to submit a Full Application, please note the Full Application form on the website is provided only as a sample.

The applicant(s) must prepare and submit the Full Application according to the instructions.

The Full Application must be complete and contain all information and supporting documents necessary for assessment and must comply with these guidelines.

Full Applications must be submitted by the closing date/time, consideration must be given to the time needed to comply with internal deadlines.

Electronic signatures are acceptable if approval to use the electronic signature has been obtained from that person.

CRT require two copies of the Full Application, an electronic copy and a hard copy.

The Full Application hardcopy can be mailed to PO Box 226, Subiaco WA 6904 or delivered by hand to Suite 8, 110 Hay Street, Subiaco WA 6008.

The Full Application electronic copy is to be emailed to info@cancerresearchtrust.org.au as a single Adobe Acrobat PDF or Microsoft Word file, not exceeding 5 MBs, including supporting documentation.

Full Applications (electronic and hard copy) must be received by: **4:00pm (AWST) Friday 15 May 2026.**

Full Applications will be assessed by the Panel and the shortlisted applicants will be interviewed.

5.3 Selection Process

All members of the Panel will be required to declare any Conflict of Interest (COI) prior to assessing the Expression of Interest and Full Applications.

Funding will be awarded on merit, based on a process of assessment and selection. All funding decisions are final, and no further negotiations will be entered into.

CRT may request additional supporting documentation (not listed in these Guidelines) to assist the Panel in their deliberations.

CRT will make the final decision based on the recommendations from the Panel.

COIs that may arise will be treated in accordance with the NHMRC guidelines and/or the Department of Health's Managing Conflicts of Interest Policy.

In circumstances where documentation in the form of guidelines, rules or practices relating to the administration of the CCRG are not explicitly addressed, any determination will be guided by the rules and practices of NHMRC.

5.4 Timeline

A proposed timeline for the schedule of application events is:

Stage	Date
Deadline for Expression of Interest	Friday 14 November 2025
Invite applicants to complete Full Application	Friday 13 February 2026
Full Applications close	Friday 15 May 2026
Interviews held	w/c Monday 27 July 2026
Notification of successful recipient	Friday 21 August 2026

Please note: this timeline is subject to change without notice.

6 Guidance on completing the Expression of Interest and Full Application

6.1 Collaboration

Meaningful, inter-institutional collaboration will be a key success factor in the assessment of applications. Applications must involve a minimum of two Administering Institutions within WA, but three or more will be preferred.

Applicants must demonstrate that the Administering Institutions have the ability to fund their contributions.

CRT requires documentation of the collaborative arrangements between all Administering Institutions. These agreements should be in place at submission of the applicants Full Application or be provided within 6 months of the fully executed Grant Funding Agreement.

6.2 Plain Language Summary

Provide an outline of your research proposal. This should be a short explanatory abstract which could be understood by the general public should it be required for the use by the FHRI Fund, CRT or Department of Health. It should describe the short- and long-term implications of the research program. Your plain language summary should include:

- an explanation of the type of cancer you are investigating and its impact,
- aims, significance and purpose of the research,
- how you will do the research; and
- what the benefits of the research will be for Western Australians.

6.3 Chief Investigator / Co-Chief Investigators (CI/Co-CIs)

It is expected that the CI/Co-CIs of the CCRG have a major commitment to research and a significant commitment of effort to the research program. The proposed effort and role of the CI/Co-CIs needs to be detailed in the EOI and Full Application. Any variations or discontinuations of the CI/Co-CIs in the research program during the period of the grant could result in an additional review and cancellation of the CCRG should the eligibility or assessment criteria no longer be met.

6.4 Principal Investigators (PI)

A PI is a researcher who leads and makes a substantial essential contribution to a component of the research program. Their area of expertise, time commitment and the responsibilities must be set out in the EOI and Full Application as well as their time commitment to the research. There may be one or more PIs included in the research program. The PIs must be based at an Administering Institution in WA for at least 75% of each year for the entire grant period.

6.5 Associate Investigators (AI)

AIs are researchers who contribute in a meaningful manner to the research by carrying out parts of the research program and/or providing essential expertise and/or resources. AIs may be based at an Administering Institution in WA, elsewhere in Australia or overseas. In all cases the role and the time commitment to the research of each AI should be described

Please note: only those investigators who are actively involved in, and contribute in, a meaningful manner to the proposed research program of research should be listed in the application.

6.6 Consumer Involvement

In line with the NHMRC definition, consumers are people who have lived experience of a health issue. They include patients and potential patients, carers, and people who use health care services. Consumers can also be people who represent the views and interests of a consumer organisation, a community or a wider constituency.

Health consumers should be engaged during the development of funding applications and embedded in the proposed research by being provided with a detailed description of their role and contribution and, where appropriate, included as a team member.

Guidance on consumer involvement can be found at the Consumer and Community Involvement Program website and the NHMRC Statement on Consumer and Community Involvement in Health and Medical Research 2016.

It is recommended that all team members complete the free online 30-minute Consumer and Community Involvement in Health Research course (or equivalent) and for the Activity Lead to complete the free online 30 minute Consumer & Community Involvement and Grant Writing e-course.

7 Scientific Assessment Criteria

The EOI and Full Application will be assessed on its relevance to cancer treatment and control, with priority given to those research programs that bring different disciplines and Administering Institutions together, while attracting and/or retaining research talent in WA.

7.1 EOI Scientific Criteria

7.1.1 Research Details**:**

- rationale, justification and hypotheses.
- research objectives.
- research methodology and design.
- anticipated outcomes.
- opportunities for translational gain.

7.1.2 Research Innovation:

- what is innovative about the research.
- how the research will address a current gap in cancer and the new evidence it will provide.

7.2 Full Application Scientific Criteria

7.2.1 Scientific Excellence:

- Scientific excellence including innovation, potential for translation and contribution to knowledge.

7.2.2 Research Achievements:

Research achievement of the team including:

- Track record: including the “10 most important papers” and advances made over the past 5 years,
- Key contributions to translation (e.g. commercialisation, clinical outcomes, public health changes, other cancer control strategies),
- Role and contribution to the proposed research.

7.2.3 Research Strategy:

The strategy should be feasible and consistent with research that is broadly based, multidisciplinary and collaborative. Consideration should be given to:

- Innovative ‘big picture’ research activities.
- National and International competitiveness.
- Strategy for attracting external peer review funding; and
- Specified Key Performance Indicators (KPIs) outlining the programed outcomes.

7.2.4 Collaborative Gain and Capacity Building.

Strategies for:

- Integration of the research teams, particularly across Administering Institutions and between disciplines.
- Network building.
- Intellectual exchange

Given the importance of WA capacity building, applications must detail their commitment to building capacity for cancer research within WA and how the applicants intend to achieve this, including development of team skills as well as recruitment, retention and development of Senior and/or Early-Career Research (ECR) Investigators.

7.2.5 Outcomes for Cancer.

Significance to cancer research and health outcomes. Responses explaining:

- what key questions relevant to cancer are addressed by the proposed research.
- how sustainable are the outcomes likely to be.
- the expected legacy to WA as a consequence of the research.

7.2.6 Demonstrated Consumer Involvement.

Consumer Involvement should include:

- a willingness to include consumers in the research team where appropriate.
- demonstrated understanding of the benefits derived from involving people with a lived experience.
- how consumer representatives or community groups have been or will be consulted to engage and contribute throughout the research program timeline.

8 Equipment

An Administering Institution to which equipment is entrusted must undertake to maintain the items in good and working condition and in a location where the funded research program is being conducted. Equipment bought using funds from the CCRG remains part of the research program but once the research program is satisfactorily completed, the equipment becomes the property of the Administering Institution. The Administering Institution shall not acquire any equipment or apparatus for the research program with the CCRG other than as disclosed in the grant application without the consent of the CRT. No consent is required for pieces of equipment with a purchase price of less than $50,000.

9 Consumables

Support for consumables is based on NHMRC guidelines.

10 Other Funding Sources

As well as the additional funding equating to at least 30% of the CCRG funding required as a condition of CCRG, applicants are encouraged to leverage this grant to obtain further funding support for the duration of the grant. Successful recipients are expected to use this award as base for future funding from Category 1 funding sources.

Funds received from organisations that are in conflict with the prevention of cancer will be examined closely to determine if a COI exists and may lead to the forfeit of the CCRG or ineligibility to apply.

11 Publicity and Acknowledgments

Public awareness and acknowledgement of both the FHRI Fund and CRT's role in funding the CCRG is crucial.

The Minister for Medical Research and/or the Department of Health WA will publicly announce the recipient(s) of the CCRG. Applicants and all related parties must withhold announcements, public statements, social media posts or issuing media releases until after the announcement by the Funding Partners.

Where a media release or impending publication is planned, it is the responsibility of both the CI/Co-CIs and the Administering Institution/s to provide CRT with adequate notice prior to the release, impending publication date or organisation of the conference to ensure the relevant media approvals are obtained and any reasonable requests from the FHRI Fund and CRT are met.

In addition, researchers may be asked to participate in the FHRI Fund, CRT or Department of Health's promotional initiatives.

The application title, applicants name, funding amount, Administering Institution/s, plain language summaries and sections indicated on applications or reports may be used for publicity and reporting purposes by the FHRI Fund, CRT and the Department of Health. All other information provided in applications and reports will be maintained confidentially by the FHRI Fund, CRT, Department of Health and the Panel.

If requests are received to make public any aspect of the research, other than the aspects listed above, the authorisation of the nominated Administering Institution/s will be sought, notwithstanding information requested under the Freedom of Information Act 1992 (WA) or information pertaining to the receipt of State Government financial assistance tabled in the Parliament of Western Australia.

12 Publications Arising from Grants

We encourage successful applicants to publish and disseminate results and other information from the funded research. Such publications would occur through the normal acceptable scientific channels and must always include an acknowledgement that the research was funded by the CCRG and must include the following footnote*: "[name of research scholar] was supported by a WA Collaborative Cancer Research Grant co-funded by the Future Health Research and Innovation Fund and Cancer Research Trust"*. Notification of all published papers are to be included in the recipients' annual reports submitted to CRT. A copy of the

published paper should also be forwarded to info@cancerresearchtrust.org.au as soon as practicable after the published date.

13 Reporting Obligations

In fulfillment of the conditions of an award, an annual report of the research program is required each year during the CCRG grant period. The report must be submitted by the due date specified in the Grant Funding Agreement. Failure to submit a report by the due date may jeopardise ongoing funding of the research program. The reports will be used by the FHRI Fund and CRT to monitor progress of the research program and will also be considered in the independent research program evaluation to determine if the CCRG will be renewed for a further 4 years.

A reporting template will be provided by CRT and will include the requirements to report the progress against the approved outcomes. The CI/Co-CIs and any appropriate representatives are required to attend the CRT Board meetings to present their annual reports. The CI/Co-CIs (and/or appropriate representatives) must also attend CRT Board meetings 6 months after each annual report presentation to provide informal, verbal updates on the progress of research program.

In addition, supplementary reports will be required 12 months and 5 years after the submission of the end-of-research program report to provide continuing progress reports against the original outcomes and resulting impact of the program of research.

14 Program Evaluation

Evaluation of the CCRG funding program may occur from time to time which will include unsuccessful applications. All parties in the applications, including team members are required to contribute to the evaluation.

15 Insurance

The Administering Institution will be required to provide evidence of insurance as a condition of the Grant Funding Agreement (or equivalent), which may include:

- Public Liability (mandatory for all grants).
- Professional Indemnity (mandatory if the Administering Institution is conducting a clinical trial, provides any form of medical treatment or advice, training, or will provide any tailored design, advice or specification services).
- Property for the Administering Institution's replacement value of assets (mandatory for building, plant, machinery, equipment).
- Workers Compensation (mandatory if the Administering Institution has employees or is paying salaries, noting this includes payments to working Directors).
- Product Liability (mandatory if the Administering Institution manufactures, supplies, sells, services or repairs a product).
- Motor Vehicle if the Administering Institution owns vehicles.
- Clinical Trials if the Administering Institution undertakes clinical trials (note this insurance may include Professional Indemnity).
- Cyber Liability if the Activity involves confidential data, e.g. identifiable patient information.

The Funding Partners recommend that you seek advice from your insurance advisors to confirm what level and type is required for the research program.

The Administering Institution/s is responsible for ensuring participating entities have appropriate insurance.

Note: Any research program that requires site governance approval will also be required to provide evidence of appropriate insurance during the governance process, which may vary depending on the site.

16 Requests for Variation

Any changes in CI/Co-CIs or their circumstances (including change of research location, Administering Institution, changes in time commitment, or relocation to another state/country), during the tenure of the CCRG may result in termination of the research program before expiration of the approved term of support.

Any changes or variation in the research, program, strategy or any details that varies from the information originally provided in the Full Application must be approved by CRT in writing.

The CI/Co-CIs must request approval for any variation or change in writing and advise what, if any, arrangements will be made to complete the research program for which the CCRG was awarded and provide a written report of the progress of the research program to that date. A decision to continue funding will be made based on the information supplied and following any other investigations that are deemed necessary.

In the event where a need arises for the administration of the CCRG to be transferred from one Administering Institution to another, a written request for this transfer must be made to the CRT providing reasons for the transfer. The transfer must not be made without the written consent of the CRT.

Requests for variations to the Grant Funding Agreement must be directed to the CRT. Approval of the variation will be at the discretion of the Funding Partners. If variations are not approved, this could result in termination of the grant with associated funding reverting to, or being recoverable by, the FHRI Fund, CRT, and Department of Health.

17 Research Ethics and Governance

The Administering Institution(s), and any participating entity, will be responsible for obtaining and lodging all relevant research ethics and governance approvals that are required for undertaking funded activities, and ensuring these are maintained as required for the duration of the program.

Research ethics approvals must be obtained from relevant ethics committees (human and/or animal). Research governance authorisation (also known as site specific assessment or access request review) must be obtained from each relevant institution/site conducting the program or providing access to data, participants or tissue samples.

For information on research ethics and governance submission requirements for the WA public health system please refer to the following websites: Research Ethics; Research Governance; Multi-centre Research.

18 Use of Data Collections

A research program that requires access to and use of WA Department of Health data collections requires review and approval for data release in accordance with the Health

Services Act 2016 and the Health Services (Information) Regulations 2017. This is in addition to research ethics and governance approvals and will include a feasibility assessment to determine whether the data requested is appropriate for the purposes of the study and approval for use of the data from the data custodian.

Preliminary cost and time estimates can be obtained by contacting DataServ@health.wa.gov.au. Cost estimates should be included in the proposed budget and an estimate of time for release of the data should be incorporated into the milestones in the Application Form.

For further information please review the Data Linkage Services website.

19 Intellectual Property

Intellectual Property (IP) that arises out of the research program will vest with the Administering Institution. However, consideration will be given to the provisions of the Western Australian Government Intellectual Property Policy 2023 (or any future iterations of this), and that IP rights should be allocated to optimise the economic, social or environmental benefits for WA from the use, commercialisation and disposal of the IP.

Subject to any confidentiality provisions, the Administering Institution will grant to the WA Department of Health, a non-exclusive, irrevocable, perpetual, royalty-free licence to use (excluding the ability to sub-licence or grant further licences) any of the Intellectual Property generated in the research activity, and which falls within the scope of WA Health's normal activities. This includes, but is not necessarily limited to, activities related to healthcare provision, teaching, training and research. This license does not automatically extend to any potential or eventual commercial development of the Intellectual Property, and any commercial products that might directly or indirectly result from the research activity Intellectual Property.

However, where the Administering Institution/s believes that there is the potential for commercialisation of the Intellectual Property developed in the course of the research program, all Parties shall negotiate in good faith the appropriate legal and beneficial interests, rights and access to the Intellectual Property by WA Department of Health. Where IP is created jointly by personnel from two or more Administering Institutions, the Parties shall negotiate in good faith a joint ownership and management agreement, covering matters such as prosecution, maintenance, exploitation, cost-sharing, and revenue distribution. If all contributors to the development of the IP, negotiating in good faith, are not able to agree their respective shares in the IP, then the shares shall be determined by a senior counsel appointed by the Law Society of Western Australia, acting as an expert and not as an arbitrator, and his or her decision shall be final.

Where relevant, agreements between the CI/Co-CIs, team members and participating Administering Institutions must include relevant permissions to use third-party IP required to deliver the program and have Freedom to Operate for the research program.

When a team includes a member(s) from the WA public health system as a participant in the research program (i.e., the WA public health entity is not the Administering Institution), the IP

agreement must be authorised at an appropriate level by the relevant WA public health system entity.

Prior to the start of the grant period, the CI/Co-CIs should ensure that any existing IP and its ownership is documented (“Background IP”). If any Intellectual Property is developed or any commercialisation occurs as a result of the funded research, inventorship and ownership (“Foreground IP") shall be determined based on the actual inventive or creative contribution of personnel from each collaborating Administering Institution and their internal policies.

20 Grant Conditions

Payments commence no earlier than 1 July 2026 and will be made quarterly in advance.

Payments in respect of the CCRG shall be within the terms and conditions specified in the Grant Funding Agreement.

The research program must commence within 6 months from the date of the first payment. Commencement delays of more than 6 months from the first payment requires written approval from CRT. Failure to obtain written approval from CRT for the delay will result in the CCRG being forfeited.

Grant amounts are exclusive of GST. All funding claims are to be made via a tax invoice from the nominated Administering Institution and include their ABN. This is to avoid paying withholding tax which would effectively reduce the overall grant by 48.5%. The invoice from the nominated Administering Institution to CRT must also include GST (i.e. your invoice must include an additional 10% for the GST).

Grants are paid in quarterly installments on receipt of a tax invoice from the Administering Institution. The initial invoice for claims must be generated at the commencement of the research program.

Any variations of 10% or more from the expenditure against individual budget categories outlined in the Full Application must be reported to the CRT and approved in writing.

It is a requirement of the Funding Partners that you disclose to CRT, any funding received from other sources.

In exceptional/extenuating circumstances, and upon formal application, the CRT may, at its discretion, approve a variation to the payment method outlined above.

At the completion of the grant period, all funds that are uncommitted must be repaid to the CRT, unless permission is sought and obtained in writing to use any residual funds to complete the work specified in the Full Application.

The CCRG must be spent wholly for the purposes for which it was requested and so certified by the CI/Co-CIs and the Administering Institution/s.

During the fourth year of the awarded CCRG, the research program will be formally evaluated by an external assessment panel to determine progress to date, future opportunities for the research program and recommended next steps. The CRT will consider the findings and

recommendations of the review in its determination of a potential offer of renewed funding for a further 4 years.

Termination of Funds

Funds shall revert to, or be recoverable by the Funding Partners in instances where:

- eligibility requirements are no longer met, unless a request for variation has been approved in writing by the CRT.
- information provided in the Full Application changes or varies without a request for variation being approved in writing by the CRT.
- the research program is terminated by the CRT as a result of insufficient progress being made at the time of an annual report, or it has been otherwise determined by either the Administering Institution/s or CRT that the research program is no longer viable.
- funds are used for purposes other than those for which they were awarded.
- funds were spent on activities that require ethics and/or governance approvals, and such approvals were not obtained before undertaking the activities.
- funds are not fully expended at the conclusion of the research program (including any authorised extensions approved by CRT).
- it is determined that misleading or fraudulent information has been provided.

21 Further Information

Administering Institution/s or CI/Co-CIs who feel that their interests have been adversely affected by an action taken by the CRT in administering the CCRG may lodge a complaint. Complaints can only be considered when they refer to the administrative process and not to the funding decision. Complaints must be submitted via email (marked Confidential) to:

> Project Manager, WA Collaborative Cancer Research Grant, Cancer Research Trust, (info@cancerresearchtrust.org.au).

Queries about completion of applications and the process should be addressed to:

> Project Manager, WA Collaborative Cancer Research Grant, Cancer Research Trust
> Telephone: +61 (0) 424 608 096
> E-mail: info@cancerresearchtrust.org.au